ACUR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 00:40):

Stats
今日成交量	780.00
平均成交量	1 050.00
市值	198 005
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Ross George K	Buy	50 000	Common Stock
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Ross George K	Sell	50 000	Restricted Stock Units (2021 Plan)
2024-01-02	Skelly William G	Buy	50 000	Common Stock
2024-01-02	Skelly William G	Sell	50 000	Restricted Stock Units (2021 Plan)

INSIDER POWER
7.88
Last 100 transactions
Buy: 88 557 065 \| Sell: 8 647 538

ACURA PHARMACEUTICALS INC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ACURA PHARMACEUTICALS INC 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2020
营收:	$3.57M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0400

FY	2019
营收:	$2.66M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.140

Financial Reports:

No articles found.

ACURA PHARMACEUTICALS INC

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.